<h4>Background</h4>This work assessed the value of novel thrombus markers-thrombin-antithrombin complex (TAT), plasmin-a2-plasmin inhibitor complex (PIC), thrombomodulin (TM), and tissue plasminogen activator-inhibitor complex (t-PAIC) applied in patients with respiratory failure (RF), including their role in predicting thrombus formation, evaluating prognosis, and assessing disease severity.<h4>Methods</h4>Eighty patients with RF were enrolled and categorized into mild (n = 10), moderate (n = 9), and severe (n = 71) groups based on disease severity. This evidence concerns the gene PLG and respiratory failure.